Drug Trial Radar · NCT06307431
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
272
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jan 8, 2028
Study completion Jun 8, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Conditions
- Renal Cell Carcinoma
Interventions
Intismeran autogeneBiological
IM injection
PembrolizumabBiological
IV infusion
PlaceboBiological
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS)Time frame: up to ~43 months
Locations
63 sites in 14 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104)
Duarte, California
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
Los Angeles, California
UCSF Medical Center at Mission Bay ( Site 0108)
San Francisco, California
Yale-New Haven Hospital-Yale Cancer Center ( Site 0102)
New Haven, Connecticut
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109)
Boston, Massachusetts
Dana-Farber Cancer Institute-GU ( Site 0101)
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center ( Site 0100)
New York, New York
Duke Cancer Institute ( Site 0106)
Durham, North Carolina
Abramson Cancer Center ( Site 0107)
Philadelphia, Pennsylvania
Fox Chase Cancer Center ( Site 0111)
Philadelphia, Pennsylvania
UT Southwestern Medical Center ( Site 0110)
Dallas, Texas
Hospital Británico de Buenos Aires-Oncology ( Site 1106)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 1101)
Buenos Aires, Buenos Aires F.D., Argentina
Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110)
Buenos Aires, Buenos Aires F.D., Argentina
Centro Privado de RMI Rio Cuarto ( Site 1104)
Río Cuarto, Córdoba Province, Argentina
Fundacion Estudios Clinicos ( Site 1111)
Rosario, Santa Fe Province, Argentina
Macquarie University-MQ Health Clinical Trials Unit ( Site 1502)
Macquarie University, New South Wales, Australia
Westmead Hospital ( Site 1501)
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, Australia
Fiona Stanley Hospital-Medical Oncology ( Site 1503)
Murdoch, Western Australia, Australia
BC Cancer Vancouver ( Site 0005)
Vancouver, British Columbia, Canada
CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008)
Québec, Quebec, Canada
FALP-UIDO ( Site 1202)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 1205)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 1201)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 1200)
Viña del Mar, Valparaiso, Chile
Hôpital Européen Georges Pompidou ( Site 0300)
Paris, France
CENTRE LEON BERARD ( Site 0305)
Lyon Cedex08, Auvergne-Rhône-Alpes, France
CHU Besançon ( Site 0302)
Besançon, Doubs, France
Institut Claudius Regaud ( Site 0303)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 0304)
Villejuif, Île-de-France Region, France
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0401)
Berlin, Germany
Asklepios Altona-Department of Urology ( Site 0410)
Hamburg, Germany
Klinikum Stuttgart - Katharinenhospital ( Site 0400)
Stuttgart, Baden-Wurttemberg, Germany
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Sit
Munich, Bavaria, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)
Dresden, Saxony, Germany
Universitätsklinikum Jena ( Site 0402)
Jena, Thuringia, Germany
Azienda Ospedaliero Universitaria di Parma ( Site 0503)
Parma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0501)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0500)
Milan, Lombardy, Italy
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.